ORPHA:251636
Ependymoma
Also known as: Classic ependymoma
Publications
20,137
97.2th percentile
Trials
149
Interventional, condition-specific
Researchers
1,486
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Ependymoma is the most frequent intramedullary tumor in adults (but accounts for only 10-12% of pediatric central nervous system tumors), and can be benign or anaplastic. Ependymoma arise from the ependymal cells of the cerebral ventricles, corticle rests and central canal of the spinal cord, and manifest with variable symptoms such headache, vomiting, , focal neurological signs and loss of vision and can cause obstructive hydrocephalus in some cases.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016698
- MeSH:D004806
- UMLS:C0014474
- NCIT:C3017
Additional Mondo synonyms (2)
benign ependymoma · ependymoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
20,137 matched papers (10,921 in last 10 years) Source
- Phenotype characterisedPresent
31 HPO annotations (e.g. Adult onset; Vomiting; Ependymoma) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
149 matched on ClinicalTrials.gov (25 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
31
Associated phenotypes · MONDO:0016698
- Adult onset
- Vomiting
- Ependymoma
- Distal muscle weakness
- Pain
Showing 5 of 31 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
72
Drugs / clinical candidates · MONDO_0016698
- CARBOPLATIN·phase 3
- CISPLATIN·phase 3
- CYCLOPHOSPHAMIDE·phase 3
- ETOPOSIDE·phase 3
- METHOTREXATE·phase 3
- TEMOZOLOMIDE·phase 3
- THIOTEPA·phase 3
- VINCRISTINE·phase 3
- ABEMACICLIB·phase 2
- ANTINEOPLASTON A10·phase 2
- BEVACIZUMAB·phase 2
- BRIGATINIB·phase 2
- CELECOXIB·phase 2
- CYTARABINE·phase 2
- ERLOTINIB·phase 2
CTD chemicals (MyDisease.info)
5 associated chemicals · 72 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Carmustine · therapeutic
- Methotrexate · therapeutic
- Procarbazine · therapeutic
- Thalidomide · therapeutic
- Vincristine · therapeutic
Pathways: Axon guidance; Synaptic vesicle cycle; Insulin secretion; Neurotransmitter Release Cycle; Transmission across Chemical Synapses; Neuronal System; IRS-mediated signalling; SOS-mediated signalling
Literature
Is anyone studying this?
20,137
20,137 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
20,137 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
10,921 in the last 10 years · medium confidence · 97.2th percentile (publications denominator)
Phrase hits: 20,137 · MeSH hits: 402
Who's working on it?
1,486
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ichimura K6 papers · 2026
Department of Pathology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Papers in Europe PMC - 02Liu Y6 papers · 2026
Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Papers in Europe PMC - 03Wang Y6 papers · 2026
Department of Radiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China. doctorwang1005@163.com.
Papers in Europe PMC - 04Hirato J5 papers · 2026
Department of Pathology, Public Tomioka General Hospital, Tomioka, Japan.
Papers in Europe PMC - 05Merchant TE5 papers · 2026
Chair, Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, United States. Electronic address: thomas.merchant@stjude.org.
Papers in Europe PMC - 06Tabori U5 papers · 2026
Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada.
Papers in Europe PMC - 07Wang C5 papers · 2026
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Papers in Europe PMC - 08Ellison DW4 papers · 2026
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Papers in Europe PMC - 09Mack SC4 papers · 2026
Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Papers in Europe PMC - 10Pfister SM4 papers · 2026
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
149
interventional trials for this specific condition
149 interventional trials matched this specific condition name; 25 currently recruiting in our sample.
Data as of 9 September 2026
149 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99th percentile).
medium confidence · 99th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
149 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06161519·RECRUITING·PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Confirmed·Conditions: Glioma · Medulloblastoma · Ependymoma · Glioblastoma·Matched via name + MeSHBoth providers judged relevant.
- NCT05106296·RECRUITING·Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Confirmed·Conditions: Ependymoma · Medulloblastoma · Glioblastoma · Primary Brain Tumor·Matched via name + MeSHBoth providers judged relevant.
- NCT01356290·RECRUITING·Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Confirmed·Conditions: Medulloblastoma Recurrent · Ependymoma Recurrent · ATRT Recurrent · Rare CNS Tumor Recurrent·Matched via name + MeSHBoth providers judged relevant.
- NCT06607692·RECRUITING·Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Confirmed·Conditions: Solid Tumor Cancer · Medulloblastoma · High Risk Neuroblastoma · High Grade Gliomas·Matched via name + MeSHBoth providers judged relevant.
- NCT04541082·RECRUITING·Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Confirmed·Conditions: Central Nervous System Neoplasms · Glioblastoma · Gliosarcoma, Adult · Anaplastic Oligodendroglioma·Matched via name + MeSHBoth providers judged relevant.
- NCT04732065·RECRUITING·ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Confirmed·Conditions: Diffuse Midline Glioma (DMG) · Glioblastoma · Recurrent Ependymoma · Recurrent Malignant Central Nervous System Neoplasm·Matched via name + MeSHBoth providers judged relevant.
- NCT07017816·RECRUITING·A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
Confirmed·Conditions: CNS Malignancies · Medulloblastoma Recurrent · ATRT Recurrent · Pineoblastoma·Matched via name + MeSHBoth providers judged relevant.
- NCT06193759·RECRUITING·Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Confirmed·Conditions: Medulloblastoma, Childhood · Atypical Teratoid/Rhabdoid Tumor of CNS · Embryonal Tumor With Multilayered Rosettes · Pineoblastoma·Matched via name + MeSHBoth providers judged relevant.
- NCT07226453·RECRUITING·Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
Confirmed·Conditions: Posterior Fossa Ependymal Tumor·Matched via name + MeSHBoth providers judged relevant.
- NCT07707947·NOT YET RECRUITING·Selumetinib for NF2-Related Schwannomatosis
Uncertain·Conditions: Neurofibromatosis Type 2 · NF2 · NF2-related Schwannomatosis · Meningioma·Matched via name + MeSHAt least one provider returned uncertain or parent-category.
- NCT04374305·RECRUITING·Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Parent·Conditions: Neurofibromatosis Type 2 · Vestibular Schwannoma · Non-vestibular Schwannoma · Meningioma·Matched via name + MeSHBoth providers judged relevant only to a broader parent category.
- NCT07664176·NOT YET RECRUITING·NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
Confirmed·Conditions: Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma · High Grade Gliomas · Medulloblastoma Recurrent · Ependymoma Recurrent·Matched via name + MeSHBoth providers judged relevant.
- NCT06804655·NOT YET RECRUITING·Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Confirmed·Conditions: Brain (Nervous System) Cancers · Glioblastoma · Glioma · Ependymoma·Matched via name + MeSHBoth providers judged relevant.
- NCT05278208·RECRUITING·Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Confirmed·Conditions: High Grade Glioma · Meningioma · Embryonal Tumor · Medulloblastoma·Matched via name + MeSHBoth providers judged relevant.
- NCT07424092·RECRUITING·Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
Confirmed·Conditions: High Grade Glioma · Ependymoma · Embryonal Tumor of Brain · Recurrence·Matched via name + MeSHBoth providers judged relevant.
Observational and natural-history studies
20 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05259605·RECRUITING·Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Confirmed·Conditions: Glioma · Glioneuronal Tumor · Choroid Plexus Tumor · Pineal Tumors·Matched via name + MeSHBoth providers judged relevant.
- NCT07703605·NOT YET RECRUITING·AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors
Uncertain·Conditions: Pediatric Brain Tumors · Glioma · Medulloblastoma · Ependymoma·Matched via name + MeSHAt least one provider returned uncertain or parent-category.
- NCT07589361·NOT YET RECRUITING·Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors
Confirmed·Conditions: Pediatric Central Nervous System Tumors · Medulloblastoma · Germinoma · Ependymoma·Matched via name + MeSHBoth providers judged relevant.
- NCT06323408·NOT YET RECRUITING·Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas
Confirmed·Conditions: Glioma, Malignant · Embryonal Tumor · Medulloblastoma · Ependymoma·Matched via name + MeSHBoth providers judged relevant.
- NCT05672043·RECRUITING·Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Confirmed·Conditions: Medulloblastoma · Central Nervous System Tumor, Pediatric · Ependymoma · Germ Cell Tumor·Matched via name + MeSHBoth providers judged relevant.
- NCT06499636·NOT YET RECRUITING·In Vitro Models From Pediatric Brain Tumors
Confirmed·Conditions: Glioma, Malignant · Ependymoma · Medulloblastoma·Matched via name + MeSHBoth providers judged relevant.
- NCT05151718·RECRUITING·Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
Confirmed·Conditions: Ependymoma of Brain · Pediatric Solid Tumor·Matched via name + MeSHBoth providers judged relevant.
- NCT04648462·RECRUITING·Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
Confirmed·Conditions: Astrocytoma · Ependymoma · Ganglioglioma · Oligodendroglioma·Matched via name + MeSHBoth providers judged relevant.
- NCT06779487·RECRUITING·Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline
Confirmed·Conditions: Brain Tumors · Medulloblastoma · Glioma · Ependymoma·Matched via name + MeSHBoth providers judged relevant.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 2 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
- ctis·2024-512222-28-00·Authorised, ongoing·SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
Confirmed — Both providers judged relevant.
- ctis·2023-509585-38-00·Authorised, ongoing·MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medulloblastoma and ependymoma
Confirmed — Both providers judged relevant.
Uncertain / not reviewed (3)
- ctis·2025-521180-13-00·Authorised, ongoing·PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors.
Uncertain — At least one provider returned uncertain or parent-category.
- ctis·2024-513470-22-00·Cancelled·Metro-PD1-1708: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors
Uncertain — At least one provider returned uncertain or parent-category.
- ctis·2024-515626-92-00·Authorised, ongoing·MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors
Uncertain — At least one provider returned uncertain or parent-category.
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Ependymoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Ependymoma" OR "Classic ependymoma" OR "benign ependymoma"
MeSH descriptor terms unioned into the query: Ependymoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Ependymoma" OR "Classic ependymoma" OR "benign ependymoma"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 149 interventional · 20 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T02:04:26.390Z
